PARP Inhibitors in Cancers: 2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 April 2026) | Viewed by 1275
Special Issue Editor
Interests: PARP; hypoxia; tumor microenvironment; PARP inhibitor; mitochondrial diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology has heralded the clinical development of a wide range of chemical inhibitors that target several enzymes involved in signal DNA damage, modulating chromatin architecture or inhibiting specific DNA repair pathways, and whose activity is certainly uncontrolled in cancer cells. Poly (ADP-ribose) polymerase (PARP) inhibitors represent a novel and effective class of anti-cancer therapy, highlighting the importance of the synthetic lethality concept in cancer progression, focusing on cells lacking homologous recombination DNA repair. Biochemically, PARP inhibition leads to the accumulation of DNA damage by impairing single-strand break sites, trapping DNA-dependent PARP at these SSBR sites and leading to the inhibition of DNA replication.
However, the mechanism is much more complex and the biology of PARP enzyme inhibition is still far from fully understood. This dearth of information has triggered a multitude of projects and groups to open new lines of research on cancer, neurodegenerative diseases, and metabolic or cardiac diseases, enriching knowledge about the therapeutic potential of PARP inhibitors.
This Special Issue welcomes both original research manuscripts and reviews focused on the current state of PARP inhibitors in cancer therapy.
Dr. Jose Manuel Rodriguez-Vargas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PARP inhibitors
- clinical relevance
- cancer progression
- DNA repair mechanisms
- cancer cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
